AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

The FDA's Single Institutional Review Board (sIRB) mandate is good news for clinical research. Learn more about how this mandate benefits everyone involved in the clinical research process.

Nanoscope Therapeutics is on the brink of filing what could be the first mutation-agnostic gene therapy for incurable eye disease retinitis pigmentosa.

The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.

Mental health issues among teens and young adults have risen dramatically over the past decade. Jessica Lake, chief science officer at Limbix, tells us about SparkRx, a digital therapeutics app ...

Engaging all stakeholders in the process of establishing a global MI service is key to its overall success. Each ...